Novo nordisk a/s: oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the oasis 1 trial

BagsvÆrd, denmark, 22 may 2023 – novo nordisk today announced headline results from oasis 1, a phase 3a trial in the global oasis programme. oasis 1 is a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities. both treatment arms were in conjunction with lifestyle intervention. the trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with oral semaglutide 50 mg versus placebo.
NVO Ratings Summary
NVO Quant Ranking